-+ 0.00%
-+ 0.00%
-+ 0.00%
Atrys Health 9M 2026 EBITDA rises 19% to EUR 14.2 million; operating cash flow more than doubles to EUR 11.3 million
Share
Listen to the news
Atrys Health 9M 2026 EBITDA rises 19% to EUR 14.2 million; operating cash flow more than doubles to EUR 11.3 million
  • Atrys Health's nine-month 2026 EBITDA rose 19% to €14.2 million, while revenue increased 10% to €117.1 million.
  • Operating cash flow more than doubled to €11.3 million, driven by EBITDA growth and greater investment discipline.
  • September-end net financial debt fell 78% from end-2025 to €37.5 million following the January sale of ASPY for €145 million.
  • Full-year 2026 targets remain unchanged at €20.5 million in reported EBITDA and €156.5 million in revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrys Health SA published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending